Cardiac fibrosis often has adverse cardiovascular effects, including heart failure, sudden death, and malignant arrhythmias. However, there is no targeted therapy for cardiac fibrosis. Inflammation is known to play a crucial role in the disorder, and the NLR pyrin domain-containing-3 (NLRP3) inflammasome is closely associated with innate immunity. Therefore, further understanding the pathophysiological role of the inflammasome in cardiac fibrosis may provide novel strategies for the prevention and treatment of the disorder. The aim of this review was to summarize the present knowledge of NLRP3 inflammasome-related mechanisms underlying cardiac fibrosis and to suggest potential targeted therapy that could be used to treat the condition.
CITATION STYLE
Fan, J., Ren, M., Adhikari, B. K., Wang, H., & He, Y. (2022). The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis. Journal of Inflammation Research. Dove Medical Press Ltd. https://doi.org/10.2147/JIR.S370483
Mendeley helps you to discover research relevant for your work.